← Back to Clinical Trials
Recruiting Phase 2 NCT00603330

Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function

Trial Parameters

Condition Graft-versus-host Disease
Sponsor University of Liege
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 100
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2008-01
Completion 2024-08
Interventions
Mesenchymal stem cells

Brief Summary

The present project aims at investigating the role of MSC for the treatment of patients with Part 1: Steroid-refractory grade II-IV acute GVHD. Part 2: Poor graft function (PGF) Part 3: Low or falling donor T-cell chimerism after allogeneic HCT. This is a multicenter phase II study examining the feasibility and efficacy of this approach.

Eligibility Criteria

Inclusion Criteria: Patient eligibility criteria 1. Male or female of any age. 2. Previous allogeneic transplantation (related or unrelated donor, any degree of HLA matching) or autologous transplantation (for part 2 only) of HSC at any time before. 3. Any source of HSC (marrow, PBSC, cord blood) and any conditioning regimen. 4. Informed consent given by donor or his/her guardian if of minor age. 5. Additional criteria for each part of the protocol: Part 1: MSC for steroid-refractory grade II-IV acute GVHD 1. Allogeneic transplantation. 2. Grade II-IV acute GVHD (see appendix A for acute GVHD grading) de novo or following DLI. 3. Acute GVHD refractory to mPDN 2 mg/kg/day or equivalent, defined as * progression of GVHD on day 3 after initiation of steroids * no improvement of GVHD on day 7 after initiation of steroids * absence of complete resolution of acute GVHD on day 14 after initiation of steroids * relapse of acute GVHD during or after steroid taper. 4. Ongoing therapy with Ciclos

Related Trials